拜恩泰科 BNTX

Annemarie Hanekamp is our Chief Commercial Officer. She joined BioNTech in 2024 and has more than 20 years of experience in the healthcare industry, including 15 years of commercial experience in companies ranging from early-stage biotechnology companies to full-scale pharmaceutical companies. She successfully delivered significant value in a broad range of roles: at Novartis, she led the U.S. and global teams through a time of strategic opportunities and operational headwinds following an unprecedented strong launch uptake of their novel treatment for prostate cancer. She was also responsible for building a new global oncology organization following a company-wide transformation. At Bristol Myers Squibb Co., she held a pivotal role in evolving the company's U.S. oncology strategy, resulting in significant and sustainable growth including an expanded market access as well as product launches. Annemarie Hanekamp holds degrees in biomedical sciences as well as organizational leadership.

Prof. Ugur Sahin, M.D., co-founded BioNTech in 2008 and has served as our Chief Executive Officer since that time. He is a physician, immunologist and leader in the development of novel approaches to fight cancer and infectious diseases. Ugur Sahin is one of the world's foremost experts on messenger ribonucleic acid (mRNA) medicines. He has pioneered several fundamental breakthroughs enabling the development of mRNA vaccines and other types of immunotherapies. He initiated and oversaw Project Lightspeed, the historic development of the first mRNA vaccine for COVID-19, moving from lab and clinical testing to conditional approval within an unprecedented 11-month period. He also leads BioNTech's research and development of neoantigen specific as well as non-neoantigen specific mRNA cancer immunotherapies, which can be individually tailored and produced on demand according to the profile of non-synonymous mutations identified by next-generation sequencing in patients' tumors. Ugur Sahin is co-inventor of more than 500 filed patents applications and patents. His academic credentials include serving as a Full Professor in Translational Oncology & Immunology at Johannes Gutenberg University in Mainz, Germany, where he was the supervisor of more than 50 Ph.D. students. He also holds the role of Chairman of the Scientific Management Board of the Helmholtz Institute for Translational Oncology (HI-TRON). Based on his contributions to scientific discovery, Ugur Sahin has received numerous awards and recognitions, including the German Sustainability Award, the Mustafa Prize, and the German Cancer Award. He is married to Ozlem Tureci.

James Ryan, Ph.D., is our Chief Legal Officer and Chief Business Officer. He has guided BioNTech through a wide range of key business, IP and transactional activities, mergers and acquisitions, strategic collaborations and equity capital markets transactions including the Company's IPO in 2019. James Ryan and his teams played a pivotal role in the successful development of the Pfizer-BioNTech COVID-19 Vaccine, supporting every legal aspect of the program, its launch and commercialization, and was also instrumental in the strategic collaboration with Bristol Myers Squibb. James Ryan joined BioNTech in 2018 and was appointed as a Member of the Management Board in 2023. He brings over 20 years of global legal and IP expertise in the pharmaceutical industry to the Company. In his prior role, he established the legal group of GW Pharmaceuticals (NASDAQ: GWPH), where he also served as Head of Legal Affairs. James Ryan also worked for a number of UK and US law firms, including Special Counsel at Covington & Burling LLP, where he specialized in commercial and strategic transactions with a focus on companies in the life sciences sector. James Ryan has a Ph.D. in epigenetics from the University of St Andrews, is a member of the Law Society of England & Wales, and a member of the Law Society of Ireland.

Sierk Poetting, Ph.D., is our Chief Operating Officer. He joined us in September 2014 from Novartis, where he had held various roles since 2006, most recently serving as Vice President and Chief Financial Officer of the Sandoz Division in North America from 2012 to 2014. Sierk Poetting started his career as a consultant with McKinsey & Company. A German citizen, he holds a Master of Science in Optical Sciences from the University of Arizona and a Ph.D. in Physics from the Ludwig-Maximilians University in Munich.

Prof. Ozlem Tureci, M.D., Co-founder and Chief Medical Officer of BioNTech, is a physician, immunologist, and cancer researcher with translational and clinical experience. She has helped lead the discovery of cancer antigens, the development of mRNA-based individualized and off-the-shelf immunotherapy candidates and other types of immunotherapies which are currently in clinical development. Ozlem Tureci leads the clinical development of BioNTech's Project Lightspeed, the company's successful effort to develop and distribute an mRNA-based vaccine against COVID-19, a historic achievement completed in less than one year. Ozlem Tureci previously served as CEO and Chief Medical Officer of Ganymed Pharmaceuticals AG, which she co-founded with Ugur Sahin and Christoph Huber. She is also a professor for Personalized Immunotherapy at the University Medical Center Mainz and the Helmholtz Institute for Translational Oncology Mainz (HI-TRON) and currently serves as President of the Association for Cancer Immunotherapy (CIMT) in Germany. She is a recipient of the German Sustainability Award, among other notable recognitions. Ozlem Tureci is married to Ugur Sahin.

Helmut Jeggle has been Chair of our Supervisory Board since its foundation in 2008. He has a degree in business administration from the University of Applied Sciences in Neu-Ulm and an MBA (Master of Business Administration) from the Stuttgart Institute of Management and Technology. From 2000 to 2007, Helmut Jeggle held various positions at Hexal AG. From 2007 onwards, he was, among other things, in charge of Direct Investments at ATHOS KG, the family office of the Strungmann family, from which he resigned as general partner (Komplementar) in April 2021. Since 2014, Helmut Jeggle has been Managing Director of Salvia GmbH, where he acts as an entrepreneurial venture capital investor. He is currently a member of two other supervisory boards of listed companies, including 4SC AG and Tonies SE.

Ulrich Wandschneider, Ph.D., has served as a member of our Supervisory Board since 2018. He has more than 20 years of experience in the healthcare sector as a manager in the operative business and as a member of boards and committees. He was a Partner at Arthur Andersen until 2002 and at Deloitte from 2002 to 2004 in the healthcare and life science sector for many years. From 2004 to 2016 Ulrich Wandschneider served as Chief Executive Officer first of Mediclin AG later of Asklepios Kliniken GmbH & Co. KGaA. In addition to BioNTech SE, he is deputy chairman of the Supervisory Board of Marienhaus GmbH, chairman of the Supervisory Board of fischerAppelt AG, chairman of the Board of Trustees of Oberberg GmbH and he serves as chairman or member of various Advisory Boards, such as chairman of the Advisory Board of Argentum Pflege Holding GmbH and Panorama Fachklinik GmbH and member of the Advisory Board of Creative Balloons GmbH.

Prof. Anja Morawietz, Ph.D., has served as a member of our Supervisory Board since 2022. She has been a professor of external accounting and general business administration at the Nuremberg University of Applied Sciences Georg Simon Ohm since 2015. Her research areas are international and national accounting, current developments in corporate governance and sustainability reporting. She also works as a freelance auditor, particularly in audit-related consulting. Previously, she worked for ten years for auditing company KPMG AG, where she conducted audits of annual and consolidated financial statements and advised clients on accounting and regulatory issues. After training as a bank clerk at Norddeutsche Landesbank in Hanover, Anja Morawietz studied business administration at Goethe University in Frankfurt am Main, where she also completed her doctorate as an external doctoral candidate.

Prof. Rudolf Staudigl, Ph.D., has served as a member of our Supervisory Board since 2022. He studied chemistry at Ludwig Maximilian University of Munich, obtaining his Ph.D. (Dr. rer. nat) in 1981. After postdoctoral research at Harvard University (Cambridge, USA) and Ludwig Maximilian University, he joined Wacker Chemitronic in 1983. Mr. Staudigl became Vice President of Operations at Wacker Siltronic Corporation (Portland, Oregon, USA) in 1989 and President a year later. He joined the Executive Board of Wacker Chemitronic in 1993. In 1995, Rudolf Staudigl was appointed to the Executive Board of Wacker Chemie. In May 2008, Rudolf Staudigl was appointed President & CEO of Wacker Chemie AG. Until July 2024, he was a member of the Supervisory Board of TUV Sud Aktiengesellschaft. He currently serves as Deputy Chairman of the Supervisory Board of Groz-Beckert and Chairman of the Supervisory Board of Zadient Technologies SAS.

Michael Motschmann has served as a member of our Supervisory Board since 2008. He co-founded MIG Verwaltungs AG, or MIG, in 2004, where he serves on the Management Board and as Head of Equity Investments. In his role with MIG, Michael Motschmann currently serves on the supervisory boards of several private portfolio companies.

Baroness Nicola Blackwood has served as a member of our Supervisory Board since May 25, 2023. She has been Chair of Genomics England since 2020 and Chair of Oxford University Innovation since 2021. She is a member of the House of Lords, the upper chamber of the Parliament of the United Kingdom (UK). Blackwood was elected Member of Parliament for Oxford West and Abingdon 2010 to 2017 and served as Minister for Innovation at the UK Department of Health and Social Care from 2016 to 2017 and 2019 to 2020 where she led on life sciences, NHS data and digital transformation and global health security. Among other roles, she was Chair of the technical regulator, the Human Tissue Authority, as well as a Chair of the UK House of Commons Science and Technology Select Committee and a member of the House of Lords Science and Technology Select Committee. Nicola Blackwood was educated at Trinity College of Music, London, St Anne's College, Oxford, and Emmanuel College, Cambridge.

Ramon Zapata is our Chief Financial Officer. He joined BioNTech in 2025 and is a seasoned global finance executive with more than 25 years of experience in the pharmaceutical and consumer goods industries. He has held leadership roles at leading global companies including Novartis, Sandoz, and Mondelez International, and has worked across Europe, North America, Latin America, and the Middle East. Throughout his career, he has led finance functions enabling seamless execution from drug discovery through commercialization, including overseeing M&A transactions and successful integrations as well as driving digital finance transformations. Prior to joining BioNTech, he served as Chief Financial Officer and Head of Scientific Operations of BioMedical Research at Novartis, where he was responsible for the overall leadership of the division's finance strategy and operations, portfolio realignment, cross-functional integration, and strategic external collaborations. He holds dual citizenship of the United States and Mexico. He is a Certified Public Accountant (CPA) from Universidad Panamericana. He holds an MBA from IPADE Business School, with academic credits earned at IESE Business School as part of the program. He also earned a postgraduate diploma in Tax Legislation from ITAM and is currently pursuing a Master's degree in Industrial-Organizational Psychology at Harvard University.

Kylie Jimenez is our Chief People Officer. She is responsible for the company's global people strategy and its execution in support of BioNTech's long-term objectives. Her remit includes leadership and succession, organizational effectiveness, culture, and people governance across the enterprise. Kylie Jimenez has held HR leadership roles across North America, Europe, and Latin America. Her experience spans multinational organizations in the pharmaceutical, industrial, consumer goods, and automotive sectors. She has overseen people and organizational transformation initiatives that aim to strengthen culture, improve effectiveness, and enable employees to perform at their best. Through her role, she supports an environment where people can grow, lead, and contribute meaningfully to BioNTech's purpose.?She holds a degree from the University of Waterloo, the Certified Human Resources Professional (CHRP) designation (Canada), and the INSEAD Certificate in Corporate Governance.